25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Precigen Inc
Buy, Hold or Sell?

Let's analyze Precigen together

I guess you are interested in Precigen Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Precigen Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Precigen Inc

I send you an email if I find something interesting about Precigen Inc.

1. Quick Overview

1.1. Quick analysis of Precigen (30 sec.)










1.2. What can you expect buying and holding a share of Precigen? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
17.5%

What is your share worth?

Current worth
$0.15
Expected worth in 1 year
$-0.27
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$-0.42
Return On Investment
-51.0%

For what price can you sell your share?

Current Price per Share
$0.82
Expected price per share
$0 - $0.97
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Precigen (5 min.)




Live pricePrice per Share (EOD)
$0.82
Intrinsic Value Per Share
$-4.94 - $-2.78
Total Value Per Share
$-4.79 - $-2.64

2.2. Growth of Precigen (5 min.)




Is Precigen growing?

Current yearPrevious yearGrowGrow %
How rich?$43.1m$154.7m-$55.4m-55.8%

How much money is Precigen making?

Current yearPrevious yearGrowGrow %
Making money-$7m-$18.2m$11.1m158.4%
Net Profit Margin-3,149.5%-920.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Precigen (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#463 / 959

Most Revenue
#351 / 959

Most Profit
#493 / 959

Most Efficient
#812 / 959
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Precigen?

Welcome investor! Precigen's management wants to use your money to grow the business. In return you get a share of Precigen.

First you should know what it really means to hold a share of Precigen. And how you can make/lose money.

Speculation

The Price per Share of Precigen is $0.8242. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Precigen.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Precigen, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.15. Based on the TTM, the Book Value Change Per Share is $-0.11 per quarter. Based on the YOY, the Book Value Change Per Share is $0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Precigen.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.20-24.4%-0.02-2.9%0.022.3%-0.09-11.0%-0.13-16.2%
Usd Book Value Change Per Share-0.18-22.3%-0.11-12.8%0.0911.5%-0.04-4.9%-0.03-3.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.1%0.000.0%0.011.7%
Usd Total Gains Per Share-0.18-22.3%-0.11-12.8%0.1011.5%-0.04-4.9%-0.02-1.8%
Usd Price Per Share1.58-1.45-1.46-3.52-13.10-
Price to Earnings Ratio-1.97--2.05--2.70--7.91--16.19-
Price-to-Total Gains Ratio-8.59--18.88--8.59-4.55--75.15-
Price to Book Ratio10.71-5.37-2.90-11.29-11.69-
Price-to-Total Gains Ratio-8.59--18.88--8.59-4.55--75.15-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.8242
Number of shares1213
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.11-0.04
Usd Total Gains Per Share-0.11-0.04
Gains per Quarter (1213 shares)-127.50-48.78
Gains per Year (1213 shares)-510.00-195.11
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-510-5201-196-205
20-1020-10301-391-400
30-1530-15402-587-595
40-2040-20502-783-790
50-2550-25603-978-985
60-3060-30703-1174-1180
70-3570-35804-1370-1375
80-4080-40905-1566-1570
90-4590-46005-1761-1765
100-5100-51106-1957-1960

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%4.036.00.010.0%6.044.00.012.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%6.014.00.030.0%11.029.00.027.5%14.033.03.028.0%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%7.00.033.017.5%8.00.042.016.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%6.014.00.030.0%13.027.00.032.5%16.031.03.032.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Precigen Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.184-0.105-43%0.094-295%-0.040-78%-0.029-84%
Book Value Per Share--0.1480.339-57%0.529-72%0.390-62%1.113-87%
Current Ratio--1.0302.143-52%2.359-56%3.409-70%3.396-70%
Debt To Asset Ratio--0.4100.298+38%0.326+26%0.568-28%0.469-13%
Debt To Equity Ratio--0.6950.432+61%0.522+33%2.229-69%1.436-52%
Dividend Per Share----0%0.001-100%0.000-100%0.014-100%
Eps---0.201-0.024-88%0.019-1162%-0.090-55%-0.133-34%
Free Cash Flow Per Share---0.087-0.067-23%-0.064-26%-0.069-21%-0.077-11%
Free Cash Flow To Equity Per Share---0.087-0.067-23%-0.171+98%-0.064-27%-0.018-79%
Gross Profit Margin--1.0001.0000%1.0000%1.005-1%1.0030%
Intrinsic Value_10Y_max---2.785--------
Intrinsic Value_10Y_min---4.942--------
Intrinsic Value_1Y_max---0.254--------
Intrinsic Value_1Y_min---0.343--------
Intrinsic Value_3Y_max---0.782--------
Intrinsic Value_3Y_min---1.168--------
Intrinsic Value_5Y_max---1.334--------
Intrinsic Value_5Y_min---2.138--------
Market Cap241195523.213-92%462374334.720423599271.840+9%427988901.600+8%1031416672.608-55%3833097866.928-88%
Net Profit Margin---81.997-31.495-62%-9.204-89%-9.753-88%-5.510-93%
Operating Margin---36.675-19.800-46%-9.256-75%-6.893-81%-4.086-89%
Operating Ratio--37.67520.798+81%10.364+264%7.882+378%5.053+646%
Pb Ratio5.587-92%10.7115.371+99%2.896+270%11.287-5%11.692-8%
Pe Ratio-1.026+48%-1.966-2.053+4%-2.698+37%-7.911+302%-16.187+723%
Price Per Share0.824-92%1.5801.448+9%1.463+8%3.525-55%13.098-88%
Price To Free Cash Flow Ratio-2.371+48%-4.546-5.539+22%-5.698+25%-14.450+218%-39.229+763%
Price To Total Gains Ratio-4.479+48%-8.586-18.882+120%-8.591+0%4.546-289%-75.152+775%
Quick Ratio--1.3353.424-61%3.273-59%4.618-71%4.410-70%
Return On Assets---0.804-0.185-77%-0.081-90%-0.119-85%-0.092-89%
Return On Equity---1.362-0.323-76%-0.119-91%-0.421-69%-0.269-80%
Total Gains Per Share---0.184-0.105-43%0.095-294%-0.040-78%-0.015-92%
Usd Book Value--43170000.00099316500.000-57%154783500.000-72%114055200.000-62%325847750.000-87%
Usd Book Value Change Per Share---0.184-0.105-43%0.094-295%-0.040-78%-0.029-84%
Usd Book Value Per Share--0.1480.339-57%0.529-72%0.390-62%1.113-87%
Usd Dividend Per Share----0%0.001-100%0.000-100%0.014-100%
Usd Eps---0.201-0.024-88%0.019-1162%-0.090-55%-0.133-34%
Usd Free Cash Flow---25430000.000-19481499.750-23%-18811750.000-26%-20081099.950-21%-22582624.975-11%
Usd Free Cash Flow Per Share---0.087-0.067-23%-0.064-26%-0.069-21%-0.077-11%
Usd Free Cash Flow To Equity Per Share---0.087-0.067-23%-0.171+98%-0.064-27%-0.018-79%
Usd Market Cap241195523.213-92%462374334.720423599271.840+9%427988901.600+8%1031416672.608-55%3833097866.928-88%
Usd Price Per Share0.824-92%1.5801.448+9%1.463+8%3.525-55%13.098-88%
Usd Profit---58792000.000-7051749.750-88%-18218250.000-69%-31596299.950-46%-41464424.975-29%
Usd Revenue--717000.0004933000.000-85%5525750.000-87%16193150.000-96%29899475.000-98%
Usd Total Gains Per Share---0.184-0.105-43%0.095-294%-0.040-78%-0.015-92%
 EOD+3 -5MRQTTM+4 -29YOY+6 -295Y+4 -3210Y+5 -31

3.3 Fundamental Score

Let's check the fundamental score of Precigen Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.026
Price to Book Ratio (EOD)Between0-15.587
Net Profit Margin (MRQ)Greater than0-81.997
Operating Margin (MRQ)Greater than0-36.675
Quick Ratio (MRQ)Greater than11.335
Current Ratio (MRQ)Greater than11.030
Debt to Asset Ratio (MRQ)Less than10.410
Debt to Equity Ratio (MRQ)Less than10.695
Return on Equity (MRQ)Greater than0.15-1.362
Return on Assets (MRQ)Greater than0.05-0.804
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Precigen Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.671
Ma 20Greater thanMa 500.874
Ma 50Greater thanMa 1000.947
Ma 100Greater thanMa 2001.203
OpenGreater thanClose0.810
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Precigen Inc

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Fundamental data was last updated by Penke on 2024-10-25 20:07:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Precigen earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Precigen to the Biotechnology industry mean.
  • A Net Profit Margin of -8,199.7% means that $-82.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Precigen Inc:

  • The MRQ is -8,199.7%. The company is making a huge loss. -2
  • The TTM is -3,149.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-8,199.7%TTM-3,149.5%-5,050.2%
TTM-3,149.5%YOY-920.4%-2,229.1%
TTM-3,149.5%5Y-975.3%-2,174.2%
5Y-975.3%10Y-551.0%-424.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8,199.7%-135.5%-8,064.2%
TTM-3,149.5%-205.3%-2,944.2%
YOY-920.4%-207.5%-712.9%
5Y-975.3%-353.5%-621.8%
10Y-551.0%-464.5%-86.5%
4.3.1.2. Return on Assets

Shows how efficient Precigen is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Precigen to the Biotechnology industry mean.
  • -80.4% Return on Assets means that Precigen generated $-0.80 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Precigen Inc:

  • The MRQ is -80.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -18.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-80.4%TTM-18.5%-61.9%
TTM-18.5%YOY-8.1%-10.4%
TTM-18.5%5Y-11.9%-6.6%
5Y-11.9%10Y-9.2%-2.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-80.4%-10.9%-69.5%
TTM-18.5%-11.8%-6.7%
YOY-8.1%-11.1%+3.0%
5Y-11.9%-12.7%+0.8%
10Y-9.2%-14.3%+5.1%
4.3.1.3. Return on Equity

Shows how efficient Precigen is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Precigen to the Biotechnology industry mean.
  • -136.2% Return on Equity means Precigen generated $-1.36 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Precigen Inc:

  • The MRQ is -136.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -32.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-136.2%TTM-32.3%-103.8%
TTM-32.3%YOY-11.9%-20.5%
TTM-32.3%5Y-42.1%+9.7%
5Y-42.1%10Y-26.9%-15.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-136.2%-13.7%-122.5%
TTM-32.3%-16.0%-16.3%
YOY-11.9%-13.5%+1.6%
5Y-42.1%-18.5%-23.6%
10Y-26.9%-19.0%-7.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Precigen Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Precigen is operating .

  • Measures how much profit Precigen makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Precigen to the Biotechnology industry mean.
  • An Operating Margin of -3,667.5% means the company generated $-36.68  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Precigen Inc:

  • The MRQ is -3,667.5%. The company is operating very inefficient. -2
  • The TTM is -1,980.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-3,667.5%TTM-1,980.0%-1,687.5%
TTM-1,980.0%YOY-925.6%-1,054.4%
TTM-1,980.0%5Y-689.3%-1,290.8%
5Y-689.3%10Y-408.6%-280.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,667.5%-286.0%-3,381.5%
TTM-1,980.0%-313.4%-1,666.6%
YOY-925.6%-222.8%-702.8%
5Y-689.3%-385.5%-303.8%
10Y-408.6%-494.6%+86.0%
4.3.2.2. Operating Ratio

Measures how efficient Precigen is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 37.68 means that the operating costs are $37.68 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Precigen Inc:

  • The MRQ is 37.675. The company is inefficient in keeping operating costs low. -1
  • The TTM is 20.798. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ37.675TTM20.798+16.877
TTM20.798YOY10.364+10.434
TTM20.7985Y7.882+12.916
5Y7.88210Y5.053+2.829
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ37.6752.842+34.833
TTM20.7983.179+17.619
YOY10.3643.300+7.064
5Y7.8824.823+3.059
10Y5.0536.520-1.467
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Precigen Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Precigen is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.03 means the company has $1.03 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Precigen Inc:

  • The MRQ is 1.030. The company is just able to pay all its short-term debts.
  • The TTM is 2.143. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.030TTM2.143-1.113
TTM2.143YOY2.359-0.216
TTM2.1435Y3.409-1.266
5Y3.40910Y3.396+0.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0303.747-2.717
TTM2.1433.923-1.780
YOY2.3594.715-2.356
5Y3.4095.960-2.551
10Y3.3966.291-2.895
4.4.3.2. Quick Ratio

Measures if Precigen is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Precigen to the Biotechnology industry mean.
  • A Quick Ratio of 1.34 means the company can pay off $1.34 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Precigen Inc:

  • The MRQ is 1.335. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 3.424. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.335TTM3.424-2.089
TTM3.424YOY3.273+0.152
TTM3.4245Y4.618-1.194
5Y4.61810Y4.410+0.208
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3353.342-2.007
TTM3.4243.522-0.098
YOY3.2734.658-1.385
5Y4.6185.922-1.304
10Y4.4106.478-2.068
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Precigen Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Precigen assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Precigen to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.41 means that Precigen assets are financed with 41.0% credit (debt) and the remaining percentage (100% - 41.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Precigen Inc:

  • The MRQ is 0.410. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.298. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.410TTM0.298+0.112
TTM0.298YOY0.326-0.028
TTM0.2985Y0.568-0.270
5Y0.56810Y0.469+0.099
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4100.338+0.072
TTM0.2980.346-0.048
YOY0.3260.308+0.018
5Y0.5680.365+0.203
10Y0.4690.379+0.090
4.5.4.2. Debt to Equity Ratio

Measures if Precigen is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Precigen to the Biotechnology industry mean.
  • A Debt to Equity ratio of 69.5% means that company has $0.69 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Precigen Inc:

  • The MRQ is 0.695. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.432. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.695TTM0.432+0.263
TTM0.432YOY0.522-0.091
TTM0.4325Y2.229-1.797
5Y2.22910Y1.436+0.794
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6950.392+0.303
TTM0.4320.439-0.007
YOY0.5220.375+0.147
5Y2.2290.450+1.779
10Y1.4360.488+0.948
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Precigen generates.

  • Above 15 is considered overpriced but always compare Precigen to the Biotechnology industry mean.
  • A PE ratio of -1.97 means the investor is paying $-1.97 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Precigen Inc:

  • The EOD is -1.026. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.966. Based on the earnings, the company is expensive. -2
  • The TTM is -2.053. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.026MRQ-1.966+0.941
MRQ-1.966TTM-2.053+0.087
TTM-2.053YOY-2.698+0.645
TTM-2.0535Y-7.911+5.858
5Y-7.91110Y-16.187+8.276
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.026-2.326+1.300
MRQ-1.966-2.468+0.502
TTM-2.053-2.987+0.934
YOY-2.698-3.444+0.746
5Y-7.911-5.905-2.006
10Y-16.187-6.278-9.909
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Precigen Inc:

  • The EOD is -2.371. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.546. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.539. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.371MRQ-4.546+2.174
MRQ-4.546TTM-5.539+0.993
TTM-5.539YOY-5.698+0.159
TTM-5.5395Y-14.450+8.911
5Y-14.45010Y-39.229+24.779
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.371-3.181+0.810
MRQ-4.546-3.267-1.279
TTM-5.539-3.527-2.012
YOY-5.698-4.590-1.108
5Y-14.450-8.076-6.374
10Y-39.229-8.938-30.291
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Precigen is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 10.71 means the investor is paying $10.71 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Precigen Inc:

  • The EOD is 5.587. Based on the equity, the company is overpriced. -1
  • The MRQ is 10.711. Based on the equity, the company is expensive. -2
  • The TTM is 5.371. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD5.587MRQ10.711-5.123
MRQ10.711TTM5.371+5.340
TTM5.371YOY2.896+2.474
TTM5.3715Y11.287-5.916
5Y11.28710Y11.692-0.405
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.5871.931+3.656
MRQ10.7111.982+8.729
TTM5.3712.197+3.174
YOY2.8962.400+0.496
5Y11.2873.585+7.702
10Y11.6924.208+7.484
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Precigen Inc.

4.8.1. Institutions holding Precigen Inc

Institutions are holding 62.27% of the shares of Precigen Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30Patients Capital Management LLC6.21051.5251181746587212034.1322
2024-06-30BlackRock Inc3.50160.000410247058-116070-1.12
2024-06-30Vanguard Group Inc2.30980.00026759360-8874-0.1311
2024-06-30Geode Capital Management, LLC1.05820.00043096679657942.1708
2024-06-30State Street Corp0.97140.00022842811173610.6145
2024-06-30Iridian Asset Management LLC0.70710.73782069145-22129-1.0582
2024-06-30D. E. Shaw & Co LP0.59080.00261728942-55944-3.1343
2024-06-30Renaissance Technologies Corp0.40410.0032118269013050012.4027
2024-06-30Charles Schwab Investment Management Inc0.37430.00031095383268562.5134
2024-06-30JPMorgan Chase & Co0.36860.00011078789-215915-16.6768
2024-06-30Northern Trust Corp0.35240.00031031316-51001-4.7122
2024-06-30Morgan Stanley - Brokerage Accounts0.34420.00011007304-1119352-52.6344
2024-06-30GMT Capital Corp0.22850.03916688306688300
2024-06-30Nuveen Asset Management, LLC0.18280.000353498300
2024-06-30EMFO, LLC0.17750.734751947500
2024-06-30Clarivest Asset Management LLC0.16820.0793492152137522.8746
2024-06-30Bank of New York Mellon Corp0.14410.0001421788193014.7954
2024-06-30Citadel Advisors Llc0.14340.000141975612295441.4263
2024-06-30Advisor Group Holdings, Inc.0.13950.001540832810968636.7283
2024-09-30SMH Capital Inc.0.12410.0571363182-196318-35.0881
Total 18.50113.182954142629+110634+0.2%

4.9.2. Funds holding Precigen Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Patient Opportunity C4.92070.840914400000-99786-0.6882
2024-08-31Vanguard Total Stock Mkt Idx Inv1.86360.00045453567145620036.429
2024-09-30iShares Russell 2000 ETF1.16110.0046339799800
2024-08-31Vanguard Institutional Extnd Mkt Idx Tr0.6530.002191109800
2024-07-31Fidelity Small Cap Index0.45120.0071320392-14727-1.103
2024-09-30iShares Russell 2000 Value ETF0.37220.0082108935600
2024-09-30State St Russell Sm/Mid Cp® Indx NL Cl C0.32150.001994070800
2024-09-30iShares Biotechnology ETF0.29090.010685123516360.1926
2024-09-30JPM Thematics Genetic Thrps C2 Acc USD0.27360.135800559-22369-2.7182
2024-08-31Fidelity Extended Market Index0.25960.00275978961290.8132
2024-09-28Schwab US Small-Cap ETF™0.25310.003974063000
2024-08-31Vanguard Russell 2000 ETF0.17430.0051510052129322.6014
2024-09-30State St Russell Sm Cap® Indx SL Cl I0.16120.004547168800
2024-03-31Acuitas US Microcap Strategy0.13410.144339250000
2023-12-31NT R2000 Value Index Fund - NL0.12940.0134378742-20492-5.1328
2024-09-30NT R2000 Index Fund - NL0.11450.0048335062263748.5439
2024-09-30BlackRock Extended Equity Market K0.11320.0021331261-141-0.0425
2024-06-30Patient Opportunity Equity0.11241.2716328910162385.1933
2024-09-30Schwab Small Cap Index0.10610.004631037900
2024-08-31Nuveen Equity Index R60.10030.000729361900
Total 11.9662.467635017545+1361994+3.9%

5.3. Insider Transactions

Insiders are holding 10.175% of the shares of Precigen Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-08-09Jeffrey Thomas PerezBUY588230.85
2023-12-28Randal J KirkBUY966861.41
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets73,160
Total Liabilities29,990
Total Stockholder Equity43,170
 As reported
Total Liabilities 29,990
Total Stockholder Equity+ 43,170
Total Assets = 73,160

Assets

Total Assets73,160
Total Current Assets23,715
Long-term Assets49,445
Total Current Assets
Cash And Cash Equivalents 9,345
Short-term Investments 10,191
Net Receivables 1,016
Other Current Assets 3,163
Total Current Assets  (as reported)23,715
Total Current Assets  (calculated)23,715
+/-0
Long-term Assets
Property Plant Equipment 19,001
Goodwill 24,918
Intangible Assets 5,091
Long-term Assets Other 435
Long-term Assets  (as reported)49,445
Long-term Assets  (calculated)49,445
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities23,023
Long-term Liabilities6,967
Total Stockholder Equity43,170
Total Current Liabilities
Short-term Debt 1,269
Accounts payable 4,846
Other Current Liabilities 16,530
Total Current Liabilities  (as reported)23,023
Total Current Liabilities  (calculated)22,645
+/- 378
Long-term Liabilities
Capital Lease Obligations 6,341
Long-term Liabilities  (as reported)6,967
Long-term Liabilities  (calculated)6,341
+/- 626
Total Stockholder Equity
Retained Earnings -2,047,001
Accumulated Other Comprehensive Income -2,909
Other Stockholders Equity 2,093,080
Total Stockholder Equity (as reported)43,170
Total Stockholder Equity (calculated)43,170
+/-0
Other
Cash and Short Term Investments 19,536
Common Stock Shares Outstanding 252,367
Current Deferred Revenue378
Liabilities and Stockholders Equity 73,160
Net Debt -3,004
Net Invested Capital 43,170
Net Working Capital 692
Property Plant and Equipment Gross 41,147
Short Long Term Debt Total 6,341



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-31
> Total Assets 
0
0
0
151,646
199,685
283,451
474,198
469,472
547,808
500,537
538,500
576,272
819,987
792,939
989,887
982,046
962,428
1,031,112
1,005,588
949,068
915,928
933,986
898,261
846,851
895,666
825,151
980,415
716,177
709,864
655,188
604,905
455,763
404,672
361,715
336,186
314,587
406,984
402,573
376,899
359,856
335,568
321,224
259,245
215,977
241,546
207,527
190,688
151,043
134,847
73,160
73,160134,847151,043190,688207,527241,546215,977259,245321,224335,568359,856376,899402,573406,984314,587336,186361,715404,672455,763604,905655,188709,864716,177980,415825,151895,666846,851898,261933,986915,928949,0681,005,5881,031,112962,428982,046989,887792,939819,987576,272538,500500,537547,808469,472474,198283,451199,685151,646000
   > Total Current Assets 
0
0
0
13,533
66,014
134,318
206,235
187,556
232,932
188,303
181,304
174,773
238,799
359,538
302,431
323,801
336,539
345,657
316,223
315,181
281,670
234,117
179,740
154,047
187,545
147,814
310,470
285,483
232,175
183,164
157,332
234,643
189,383
172,995
151,116
148,948
144,118
156,685
153,092
156,628
154,937
164,619
162,806
118,159
137,743
105,632
92,988
68,755
49,546
23,715
23,71549,54668,75592,988105,632137,743118,159162,806164,619154,937156,628153,092156,685144,118148,948151,116172,995189,383234,643157,332183,164232,175285,483310,470147,814187,545154,047179,740234,117281,670315,181316,223345,657336,539323,801302,431359,538238,799174,773181,304188,303232,932187,556206,235134,31866,01413,533000
       Cash And Cash Equivalents 
0
0
0
10,403
59,724
34,461
61,222
49,509
110,052
74,505
24,704
27,466
99,015
98,899
125,433
135,782
145,733
155,081
69,707
62,607
69,852
64,360
64,216
68,111
119,930
78,471
82,417
102,768
106,544
58,162
44,428
65,793
37,840
46,713
27,740
51,792
27,355
36,412
41,728
42,920
40,321
43,844
9,067
4,858
9,740
16,546
10,076
7,578
17,478
9,345
9,34517,4787,57810,07616,5469,7404,8589,06743,84440,32142,92041,72836,41227,35551,79227,74046,71337,84065,79344,42858,162106,544102,76882,41778,471119,93068,11164,21664,36069,85262,60769,707155,081145,733135,782125,43398,89999,01527,46624,70474,505110,05249,50961,22234,46159,72410,403000
       Short-term Investments 
0
0
0
260
274
95,454
136,672
127,980
112,755
101,046
98,380
88,495
82,461
67,431
90,864
102,528
114,659
115,667
166,839
174,602
135,377
92,804
44,502
11,558
3,573
2,658
164,876
120,072
75,277
67,641
61,605
9,260
111,332
86,292
85,358
48,325
78,331
78,694
72,684
72,240
71,821
71,453
62,260
51,092
94,351
71,888
63,679
55,277
27,280
10,191
10,19127,28055,27763,67971,88894,35151,09262,26071,45371,82172,24072,68478,69478,33148,32585,35886,292111,3329,26061,60567,64175,277120,072164,8762,6583,57311,55844,50292,804135,377174,602166,839115,667114,659102,52890,86467,43182,46188,49598,380101,046112,755127,980136,67295,454274260000
       Net Receivables 
0
0
0
707
3,761
1,305
5,349
7,357
7,419
9,808
37,568
29,264
27,079
160,730
55,866
52,294
44,600
43,716
42,219
42,485
43,201
43,637
38,253
39,841
30,719
33,822
30,307
28,078
24,881
34,457
24,971
26,228
19,979
23,995
19,360
20,427
21,357
26,671
21,083
21,471
24,866
1,871
2,454
13,804
15,522
14,406
14,105
1,575
1,162
1,016
1,0161,1621,57514,10514,40615,52213,8042,4541,87124,86621,47121,08326,67121,35720,42719,36023,99519,97926,22824,97134,45724,88128,07830,30733,82230,71939,84138,25343,63743,20142,48542,21943,71644,60052,29455,866160,73027,07929,26437,5689,8087,4197,3575,3491,3053,761707000
       Other Current Assets 
0
0
0
2,163
2,255
3,098
2,992
2,710
2,706
2,944
3,978
3,759
4,073
5,477
7,930
6,634
6,469
6,701
8,591
7,361
7,170
7,183
8,052
7,057
6,065
5,803
7,589
6,131
5,577
4,712
9,033
6,444
5,596
3,266
8,310
7,192
6,430
3,484
7,661
6,736
5,199
2,654
6,363
4,779
4,330
2,792
5,128
4,325
3,626
3,163
3,1633,6264,3255,1282,7924,3304,7796,3632,6545,1996,7367,6613,4846,4307,1928,3103,2665,5966,4449,0334,7125,5776,1317,5895,8036,0657,0578,0527,1837,1707,3618,5916,7016,4696,6347,9305,4774,0733,7593,9782,9442,7062,7102,9923,0982,2552,163000
   > Long-term Assets 
0
0
0
138,113
133,671
149,133
267,963
281,916
314,876
312,234
357,196
401,499
581,188
433,401
687,456
658,245
625,889
685,455
689,365
633,887
634,258
699,869
718,521
692,804
708,121
677,337
669,945
430,694
477,689
472,024
447,573
221,120
215,289
188,720
185,070
165,639
262,866
245,888
223,807
203,228
180,631
156,605
96,439
97,818
103,803
101,895
97,700
82,288
85,301
49,445
49,44585,30182,28897,700101,895103,80397,81896,439156,605180,631203,228223,807245,888262,866165,639185,070188,720215,289221,120447,573472,024477,689430,694669,945677,337708,121692,804718,521699,869634,258633,887689,365685,455625,889658,245687,456433,401581,188401,499357,196312,234314,876281,916267,963149,133133,671138,113000
       Property Plant Equipment 
0
0
0
18,687
18,939
18,410
17,020
16,629
18,116
17,389
35,596
38,000
38,015
40,863
42,201
42,739
44,673
46,659
54,429
64,672
61,233
84,222
93,335
112,674
107,044
103,411
107,245
128,874
162,777
161,959
144,322
86,197
83,663
62,052
63,981
44,277
41,443
44,071
43,554
45,215
43,593
16,621
16,322
15,292
14,525
14,059
14,179
14,208
19,278
19,001
19,00119,27814,20814,17914,05914,52515,29216,32216,62143,59345,21543,55444,07141,44344,27763,98162,05283,66386,197144,322161,959162,777128,874107,245103,411107,044112,67493,33584,22261,23364,67254,42946,65944,67342,73942,20140,86338,01538,00035,59617,38918,11616,62917,02018,41018,93918,687000
       Goodwill 
0
0
0
0
13,846
13,846
13,846
13,823
39,689
34,865
98,778
101,059
104,045
118,965
166,866
165,169
164,575
161,257
159,793
157,175
157,825
164,931
166,821
153,289
154,748
151,666
151,276
149,585
150,755
149,916
147,949
63,754
63,703
54,122
54,237
54,363
54,238
54,273
54,206
54,148
53,613
36,864
36,713
36,923
36,966
36,966
36,894
26,612
26,555
24,918
24,91826,55526,61236,89436,96636,96636,92336,71336,86453,61354,14854,20654,27354,23854,36354,23754,12263,70363,754147,949149,916150,755149,585151,276151,666154,748153,289166,821164,931157,825157,175159,793161,257164,575165,169166,866118,965104,045101,05998,77834,86539,68913,82313,84613,84613,8460000
       Long Term Investments 
0
0
0
0
0
0
0
0
40,212
73,545
149,194
195,222
0
101,896
212,889
199,077
136,906
89,483
0
53,170
21,476
23,901
26,642
28,685
10,745
9,624
0
18,859
19,229
39,596
24,002
1,461
1,108
859
337
0
103,610
85,269
66,926
48,562
29,914
11,877
0
0
7,460
7,127
5,271
0
0
0
0005,2717,1277,4600011,87729,91448,56266,92685,269103,61003378591,1081,46124,00239,59619,22918,85909,62410,74528,68526,64223,90121,47653,170089,483136,906199,077212,889101,8960195,222149,19473,54540,21200000000
       Intangible Assets 
0
0
0
29,506
43,681
42,972
42,263
41,956
41,269
45,406
68,216
65,947
129,308
162,234
256,284
247,535
255,460
244,314
238,581
225,615
223,074
240,360
240,897
232,877
231,883
218,838
213,244
129,291
125,868
112,526
107,141
68,346
65,489
64,759
65,018
65,396
61,230
59,942
56,914
54,115
51,427
45,933
42,416
44,455
43,848
42,656
40,426
40,701
38,717
5,091
5,09138,71740,70140,42642,65643,84844,45542,41645,93351,42754,11556,91459,94261,23065,39665,01864,75965,48968,346107,141112,526125,868129,291213,244218,838231,883232,877240,897240,360223,074225,615238,581244,314255,460247,535256,284162,234129,30865,94768,21645,40641,26941,95642,26342,97243,68129,506000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,976
2,381
7,652
1,921
1,362
1,326
1,341
1,497
10,956
1,433
1,332
1,239
1,188
1,131
45,261
871
1,025
0
949
0
0
0
0
000094901,02587145,2611,1311,1881,2391,3321,43310,9561,4971,3411,3261,3621,9217,6522,3811,976000000000000000000000000000
> Total Liabilities 
0
0
0
473,199
71,941
644,975
82,990
88,129
115,910
112,171
158,658
166,983
166,642
306,012
260,264
277,160
287,596
402,931
397,168
379,820
365,767
362,436
345,082
300,306
324,240
258,010
424,972
337,455
375,041
375,965
376,484
384,052
317,443
312,173
277,634
247,413
232,189
243,377
245,652
252,508
261,732
265,571
116,713
89,718
57,413
41,317
43,010
41,644
37,828
29,990
29,99037,82841,64443,01041,31757,41389,718116,713265,571261,732252,508245,652243,377232,189247,413277,634312,173317,443384,052376,484375,965375,041337,455424,972258,010324,240300,306345,082362,436365,767379,820397,168402,931287,596277,160260,264306,012166,642166,983158,658112,171115,91088,12982,990644,97571,941473,199000
   > Total Current Liabilities 
0
0
0
16,717
17,503
17,511
19,717
19,829
22,212
20,692
39,263
47,482
48,703
122,807
77,093
75,904
77,937
95,499
100,521
94,605
90,650
95,686
87,796
80,173
86,854
83,245
92,330
61,562
59,422
51,633
81,955
122,912
70,637
64,100
30,661
42,127
25,243
28,869
28,989
34,645
25,601
29,901
104,864
78,645
46,733
30,773
32,875
22,985
28,774
23,023
23,02328,77422,98532,87530,77346,73378,645104,86429,90125,60134,64528,98928,86925,24342,12730,66164,10070,637122,91281,95551,63359,42261,56292,33083,24586,85480,17387,79695,68690,65094,605100,52195,49977,93775,90477,093122,80748,70347,48239,26320,69222,21219,82919,71717,51117,50316,717000
       Short-term Debt 
0
0
0
49
89
255
244
30
0
0
2,046
3,948
2,047
2,300
1,789
1,491
1,429
952
1,020
1,206
798
719
673
735
822
1,063
746
1,025
5,619
5,668
38,226
37,774
37,399
36,622
5,005
3,017
3,017
2,293
2,314
1,953
1,945
1,033
83,110
44,428
15,063
1,421
1,200
1,202
1,318
1,269
1,2691,3181,2021,2001,42115,06344,42883,1101,0331,9451,9532,3142,2933,0173,0175,00536,62237,39937,77438,2265,6685,6191,0257461,0638227356737197981,2061,0209521,4291,4911,7892,3002,0473,9482,04600302442558949000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
559
841
855
32,002
33,592
33,091
32,108
421
360
359
356
355
402
355
0
82,069
43,219
13,819
0
0
0
0
0
0000013,81943,21982,069035540235535635936042132,10833,09133,59232,002855841559000000000000000000000000000
       Accounts payable 
0
0
0
632
704
1,486
949
1,057
1,973
1,799
3,575
6,267
6,904
7,322
4,546
4,967
7,537
8,204
7,866
8,478
7,950
8,221
7,852
8,701
7,842
8,444
8,522
13,420
12,601
8,563
7,395
5,917
4,777
3,650
4,233
4,598
4,295
4,937
3,624
5,405
4,415
2,668
4,201
4,068
3,809
2,510
2,351
1,726
4,716
4,846
4,8464,7161,7262,3512,5103,8094,0684,2012,6684,4155,4053,6244,9374,2954,5984,2333,6504,7775,9177,3958,56312,60113,4208,5228,4447,8428,7017,8528,2217,9508,4787,8668,2047,5374,9674,5467,3226,9046,2673,5751,7991,9731,0579491,486704632000
       Other Current Liabilities 
0
0
0
6,073
6,824
7,500
11,126
10,949
9,300
8,187
19,692
20,745
22,463
84,448
38,752
34,080
31,276
32,480
36,698
31,557
31,569
39,084
30,982
27,867
29,544
33,918
45,026
31,563
24,053
20,809
23,570
73,524
17,320
17,236
17,279
31,712
14,086
18,363
19,358
22,845
16,572
26,036
17,477
30,124
27,846
26,827
28,815
19,548
22,333
16,530
16,53022,33319,54828,81526,82727,84630,12417,47726,03616,57222,84519,35818,36314,08631,71217,27917,23617,32073,52423,57020,80924,05331,56345,02633,91829,54427,86730,98239,08431,56931,55736,69832,48031,27634,08038,75284,44822,46320,74519,6928,1879,30010,94911,1267,5006,8246,073000
   > Long-term Liabilities 
0
0
0
456,482
54,438
627,464
63,273
68,300
93,698
91,479
119,395
119,501
117,939
183,205
183,171
201,256
209,659
307,432
296,647
285,215
275,117
266,750
257,286
220,133
237,386
174,765
332,642
275,893
315,619
324,332
294,529
261,140
246,806
248,073
246,973
205,286
206,946
214,508
216,663
217,863
236,131
235,670
11,849
11,073
10,680
10,544
10,135
18,659
9,054
6,967
6,9679,05418,65910,13510,54410,68011,07311,849235,670236,131217,863216,663214,508206,946205,286246,973248,073246,806261,140294,529324,332315,619275,893332,642174,765237,386220,133257,286266,750275,117285,215296,647307,432209,659201,256183,171183,205117,939119,501119,39591,47993,69868,30063,273627,46454,438456,482000
       Long term Debt Total 
0
0
0
0
0
0
0
0
1,784
2,001
9,428
8,694
0
8,040
7,796
7,598
7,613
7,530
0
7,562
7,608
7,684
7,673
7,535
7,425
7,273
183,133
211,235
214,010
212,479
184,034
186,321
188,730
191,205
0
171,522
174,158
176,922
179,817
182,749
201,112
0
0
0
0
0
0
0
0
0
000000000201,112182,749179,817176,922174,158171,5220191,205188,730186,321184,034212,479214,010211,235183,1337,2737,4257,5357,6737,6847,6087,56207,5307,6137,5987,7968,04008,6949,4282,0011,78400000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
64,658
61,424
73,096
72,313
50,970
35,662
35,656
32,849
26,020
25,845
25,765
25,647
25,612
25,511
28,898
3,910
4,081
0
3,999
0
0
0
0
00003,99904,0813,91028,89825,51125,61225,64725,76525,84526,02032,84935,65635,66250,97072,31373,09661,42464,658000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
91,041
88,747
109,342
110,108
0
174,278
174,508
192,863
199,016
296,745
0
273,785
263,462
253,922
243,866
209,147
173,949
164,320
9,363
7,213
6,720
6,332
5,732
2,834
2,785
2,698
0
2,897
2,722
2,692
2,574
2,539
2,438
0
0
0
2,239
2,181
0
0
0
0
00002,1812,2390002,4382,5392,5742,6922,7222,89702,6982,7852,8345,7326,3326,7207,2139,363164,320173,949209,147243,866253,922263,462273,7850296,745199,016192,863174,508174,2780110,108109,34288,74791,04100000000
> Total Stockholder Equity
0
0
0
-321,553
112,666
-376,149
377,133
366,722
415,902
373,255
358,361
384,761
640,668
474,835
718,287
694,078
664,932
619,230
600,473
560,237
528,538
550,870
533,613
533,631
553,109
549,752
539,399
362,855
313,029
279,223
228,421
71,711
87,229
49,542
58,552
67,174
174,795
159,196
131,247
107,348
73,836
55,653
142,532
126,259
184,133
166,210
147,678
118,498
97,019
43,170
43,17097,019118,498147,678166,210184,133126,259142,53255,65373,836107,348131,247159,196174,79567,17458,55249,54287,22971,711228,421279,223313,029362,855539,399549,752553,109533,631533,613550,870528,538560,237600,473619,230664,932694,078718,287474,835640,668384,761358,361373,255415,902366,722377,133-376,149112,666-321,553000
   Common Stock
0
0
0
0
0
-15,600
-490,501
386,611
0
0
0
0
0
0
0
0
0
0
0
580,071
0
0
0
580,071
0
0
0
-579
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000-579000580,071000580,07100000000000386,611-490,501-15,60000000
   Retained Earnings Total Equity0000-1,911,620-1,891,301-1,868,567-1,846,391-1,933,770-1,916,135-1,915,556-1,890,522-1,860,758-1,840,708-1,823,3900-1,752,221-1,708,867-1,652,869-1,483,654-1,430,020-1,391,254-1,330,545-990,080-932,756-867,374-847,820-820,554-780,865-762,201-729,3410-656,222-607,158-542,729-510,015-471,8020-458,236-477,067-424,342-372,29900000000
   Accumulated Other Comprehensive Income 
0
0
0
-13,375
-9
14
28
52
144
81
98
-4
-3,137
-2,285
-5,195
-12,752
-11,435
-21,651
-25,302
-36,202
-32,967
-24,221
-16,750
-15,554
-9,587
-21,848
-22,900
-28,612
-28,325
-28,206
-33,102
-27,468
-1,354
-650
1,362
3,997
1,746
2,541
1,515
203
-1,699
-4,556
-7,181
-3,488
-2,699
-2,518
-3,561
-3,894
-2,797
-2,909
-2,909-2,797-3,894-3,561-2,518-2,699-3,488-7,181-4,556-1,6992031,5152,5411,7463,9971,362-650-1,354-27,468-33,102-28,206-28,325-28,612-22,900-21,848-9,587-15,554-16,750-24,221-32,967-36,202-25,302-21,651-11,435-12,752-5,195-2,285-3,137-49881144522814-9-13,375000
   Capital Surplus 
0
0
0
0
0
0
0
0
788,057
797,516
835,330
843,001
0
948,922
1,233,497
1,249,559
1,283,525
1,297,103
0
1,325,780
1,323,706
1,355,956
1,370,917
1,397,005
1,492,916
1,504,356
1,552,379
1,722,012
1,732,608
1,737,449
1,745,177
1,752,048
1,797,450
1,802,413
0
1,886,567
2,013,757
2,017,413
2,020,254
2,022,701
1,991,670
1,993,979
1,996,104
1,998,314
2,078,133
2,080,348
0
0
0
0
00002,080,3482,078,1331,998,3141,996,1041,993,9791,991,6702,022,7012,020,2542,017,4132,013,7571,886,56701,802,4131,797,4501,752,0481,745,1771,737,4491,732,6081,722,0121,552,3791,504,3561,492,9161,397,0051,370,9171,355,9561,323,7061,325,78001,297,1031,283,5251,249,5591,233,497948,9220843,001835,330797,516788,05700000000
   Treasury Stock00000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
-393,284
476,146
-552,258
757,618
356,473
788,057
797,516
835,330
843,001
1,074,944
948,922
1,233,497
1,249,559
1,283,525
1,297,103
1,310,979
745,709
1,323,706
1,355,956
1,370,917
816,934
1,492,916
1,504,356
1,552,379
1,722,400
1,732,608
1,737,449
1,745,177
1,752,048
1,797,450
1,802,413
1,838,919
1,886,567
2,013,757
2,017,413
2,020,254
2,022,701
1,991,670
1,993,979
1,996,104
1,998,314
2,078,133
2,080,348
2,082,654
2,086,863
2,088,025
2,093,080
2,093,0802,088,0252,086,8632,082,6542,080,3482,078,1331,998,3141,996,1041,993,9791,991,6702,022,7012,020,2542,017,4132,013,7571,886,5671,838,9191,802,4131,797,4501,752,0481,745,1771,737,4491,732,6081,722,4001,552,3791,504,3561,492,916816,9341,370,9171,355,9561,323,706745,7091,310,9791,297,1031,283,5251,249,5591,233,497948,9221,074,944843,001835,330797,516788,057356,473757,618-552,258476,146-393,284000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.